Breast Cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: Olanzapine 10 mg oral tablet from Rozdaro Company, once daily, along with other oral antiemetic medications, standard treatment including aprepitant 125 mg oral cap
Sponsors
Ghoum University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Over 18 years old Women with breast cancer who are candidates for neoadjuvant planned adjuvant chemotherapy
Exclusion criteria
Exclusion criteria: abnormal results of complete blood count, kidney function tests a history of or are a candidate for abdominal and pelvic radiotherapy in the week prior to the study grade 2 nausea Vomiting within 24 hours before starting treatment Active infection or any uncontrolled disease History of drug use, including marijuana or alcohol significant mental, emotional, or psychological disorders History of allergy to aprepitant, ondansetron, or dexamethasone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of nausea and vomiting. Timepoint: One day after intervention and six days after intervention. Method of measurement: Checklist and visual history. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Saboori
Ghoum University of Medical Sciences
Outcome results
None listed